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Simple Summary: Pancreatic cancer (PC) is a highly fatal malignancy. A major reason for the
poor prognosis of patients with PC is the insensitivity to most oncological treatment approaches.
It is known that regular exercise reduces the cancer risk. We have already shown that serum from
advanced prostate and colon cancer patients after exercise reduces growth and viability of cancer
cells. The aim of this study was to identify exercise-induced cytokines in serum from patients with
advanced-stage PC that regulate cancer cell proliferation and apoptosis. Our data suggest that
a mild resistance exercise training in advanced PC patients induces the release of CXCL1, IL10
and CCL4 from contracting skeletal muscle. We demonstrate that these myokines inhibit growth
and migration of PC cells, and induce PC cell death. With this report we provide new knowledge
on the cancer-protective function of exercise in PC. Our data strongly support sport therapies for
cancer patients.
Abstract: The evidence that regular physical exercise reduces the risk of developing cancer is well
described. However, the interaction between physical exercise and cancer is not fully clarified yet.
Several myokines released by skeletal muscle appear to have a direct anti-tumour function. There
are few data on myokine secretion after exercise in patients with advanced tumours. Pancreatic
cancer (PC) is a very aggressive and usually fatal cancer. To investigate the effects of exercise in PC,
the blood of advanced-stage PC patients was analysed after 12 weeks of resistance training using
whole-body electromyostimulation. After the 12-week training period, the patient serum inhibited
the proliferation and the motility of PC cells and enhanced PC cell apoptosis. The impact of exercise
training was also investigated in an exercise-mimicking in vitro model using electric pulse stimulation
of human myotubes and revealed similar anti-tumour effects on PC cells, clearly indicating direct
cancer-protective properties of activated skeletal muscle. Protein and gene expression analyses in
plasma from exercise-trained patients and in myotube cultures after in vitro exercise showed that
interleukin 10 (IL10), C-X-C motif ligand 1 (CXCL1) and C-C motif chemokine ligand 4 (CCL4) are
myokines released from activated skeletal muscle. In accordance with the effects of serum from
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exercise-trained patients, the supplementation with recombinant IL10, CXCL1 and CCL4 impaired
growth and migration of PC cells. Treatment of PC cells with these myokines upregulated caspase
3/7 expression and the cleavage of poly(ADP-ribose) polymerase, leading to enhanced PC cell death.
The identification of myokines with anti-tumour properties in advanced-stage PC patients after
exercise opens a new perspective in supportive therapy with sports and exercise for cancer patients.
Keywords: physical activity; exercise; whole-body electromyostimulation; myokine; pancreatic
cancer; proliferation; apoptosis; migration; electric pulse stimulation
1. Introduction
Regular exercise reduces the risk of cancer development, and in cancer survivors
lowers the risk of cancer recurrence and mortality [1,2]. The impact of exercise on the body
is pleiotropic and our knowledge about how exercise-triggered mechanisms affect cancer
risk and progression is incomplete. In recent years it has been shown that skeletal muscle
is an endocrine organ with anti-inflammatory and anti-cancer properties [2,3]. Pedersen
and colleagues pioneered a new area of research and found that stimulated skeletal mus-
cle secretes humoral factors; hundreds of these so-called myokines are identified so far,
although a biological function has been described for only 5% of all known myokines [4,5].
It is reported that specific exercise-related myokines provide health benefits mainly by
metabolic improvement in muscle and fat tissue, and by anti-inflammatory action; some
of these mechanisms have an indirect impact on cancer [4,6,7]. The prototype myokine
is interleukin 6 (IL6) [8–10]. IL6 is secreted by the tumour-immune system axis and has
pro-inflammatory effects, but also is a myokine that is quickly released by skeletal muscle
itself in response to contraction and attenuates inflammation [6]. Over the last 10 years,
researchers found significant evidence that myokines can also influence cancer cell growth
and viability, e.g., via the induction of apoptosis or the stimulation of the immune system
to fight the tumour [2,6,11,12].
A multitude of clinical studies have analysed the effect of physical activity and exercise
on cancer risk and cancer progression or recurrence in healthy individuals, early-stage
cancer patients and survivors, respectively. Compared to that, only a few mechanistic
studies in humans and mice have demonstrated a potential direct role of skeletal muscle
and the myokinome on cancer cell growth and viability [2,11–18]. Even less is known
about a direct anti-tumour impact of exercise in advanced-stage cancer patients, who often
are physically weakened due to a deteriorating muscle status, caused by cancer cachexia
and/or the oncological therapy. Are these patients able to effectively exercise in order to
secret certain myokines with anti-cancer effects? Cancer patients are in general encouraged
to be physically active and regular resistance training is recommended to counteract muscle
wasting and loss of muscle strength [19]. Yet, normal resistance exercise with weights
may be too exhausting for patients with advanced cancer due to their poor physical status.
Whole-body electromyostimulation (WB-EMS) training is an innovative, time-efficient
form of resistance exercise; it is less strenuous, and therefore is an advisable exercise
alternative for physically limited patients. Recently, we reported that resistance exercise
using WB-EMS is well-tolerated and feasible, and yet an effective training method which
improves body composition and function by increasing muscle mass in advanced-stage
cancer patients under oncological therapy [20].
In a recently published study, we could show that resistance training also has an
anti-cancer effect in physically weakened patients with advanced cancer. For the first
time we could demonstrate an inhibitory effect of resistance exercise using a WB-EMS
training concept on malignant cell growth and viability [21]. Using cancer cell cultures,
we found that serum from exercise-trained stage III/IV cancer patients with prostate or
colorectal carcinomas decreases human cancer cell viability. Our research further suggested
that resistance exercise influences the expression of specific genes that are involved in
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the regulation of proliferation and apoptosis in human cancer cell lines. A comparative
approach using serum from exercise-trained patients and also culture medium from skeletal
muscle cells that have been subjected to an exercise-mimicking treatment implied that
muscle-derived factors might be responsible for the anti-tumour effects of exercise [21].
Our primary objective in the present report was to identify myokines with anti-cancer
properties in the serum of exercising patients with advanced-stage pancreatic cancer (PC).
With our data we provide further insight into the relationship between exercise and a
highly lethal malignancy.
2. Materials and Methods
To investigate myokines with anti-tumour effect and their secretion from skeletal
muscle after exercise, plasma and serum of stage III/IV PC patients were analysed. Patients
were assigned to either the intervention group with resistance training using WB-EMS or
to a non-exercising control group [20].
2.1. Ethical Approval
The original pilot study was conducted according to the guidelines of the Declaration
of Helsinki, and approved by the Ethics Committee of the Friedrich-Alexander University
Erlangen-Nürnberg (Reg.Nr.155_13B, 16 July 2013). It is registered at clinicaltrials.gov.
(NCT02293239).
2.2. Clinical Study Design, Patient Recruitment and Exercise Intervention
The study protocol and patient recruitment of the original study are described in
detail in Schink et al. [20]. In brief, patients (18 years and older), who were diagnosed with
a stage III/IV solid tumour disease undergoing oncological therapy, and a performance
index (Karnofsky) between 100% and 60%, were included. The baseline characteristics of
the patients were assessed, and they were allocated to an exercise group using a WB-EMS
training concept for 12 weeks or to a non-exercising control group. Throughout the study,
all participants were counselled by a dietitian to achieve a daily protein supply of >1.0 g/kg
bodyweight according to the nutritional international guideline; patients with decreased
food intake, due to the disease or the oncological therapy, received medical nutritional
therapy. The exercise group attended WB-EMS training twice a week (20 min/training) for
12 weeks. Via electrodes, WB-EMS administers low-frequency current impulses (<100 Hz)
with a low current intensity (<100 mA) [22]. The patients wore a vest, upper-arm and
-thigh cuffs, and a hip belt with integrated electrodes (miha bodytec GmbH, Gersthofen,
Germany). The muscles of the upper arms, upper back, latissimus dorsi, chest, abdomen,
lower back, buttocks and thighs were stimulated by WB-EMS (Figure 1A) [21]. The electric
stimulation induced a periodic stimulation (bipolar impulses: frequency 85 Hz, pulse
width 350 µs) with a 6 s impulse phase followed by 4 s rest. The current intensity was set to
trigger a noticeable muscle contraction, up to a threshold before inducing discomfort/pain.
The current intensity was individually adapted for each muscle region. The individual and
local adaptations are highly relevant because of current tolerance limits and differences in
subcutaneous fat thickness of each patient [22]. The PC patients in the intervention group
performed 22.3 ± 4.3 WB-EMS training sessions out of the scheduled 24 sessions; in one
experiment we used serum of exercising and non-exercising patients with advanced gastric
cancer, prostate cancer or colorectal cancer (exercising gastric cancer patients attended
21.5 ± 2.2 sessions, exercising prostate cancer patients 20.8 ± 2.6 sessions, and exercising
colorectal cancer patients 20.5 ± 2.4 sessions (please see Supplemental Table S1 and [21]).
The WB-EMS training was individually supervised by experienced physiotherapists and
included light physical exercises [20].
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Figure 1. Resistance training using whole-body electromyostimulation (WB-EMS) and study flowchart. (A) The picture 
displays a patient during a 20 min WB-EMS training session. The exercising person wore a vest, a hip belt, and upper-arm 
and -thigh cuffs with integrated electrodes (for more details, please refer to [21]). Bipolar impulses simultaneously ad-
dressed eight large muscle groups. (B) Study overview. The PC patients participated in our previous pilot study “Effects 
of whole-body electromyostimulation combined with individualised nutritional support on body composition in patients 
with advanced cancer: a controlled pilot trial” [20]. 
2.3. Patient Serum 
Blood samples were collected at the beginning of the trial (pre), after 6 weeks of in-
tervention (mid) and at trial end after 12 weeks of intervention (post). The time between 
the administration of chemotherapy and the blood collection was at least 3 days, except 
for one exercising patient in whom chemotherapy was administered the day before the 
blood collection at study entry. In the exercise group the blood withdrawal was done 60 
min after the training session using WB-EMS (mid and post). Blood samples were centri-
fuged and serum and plasma were stored at −80 °C. For the in vitro study, we used serum 
from stage III/IV pancreatic cancer patients (exercise group n = 6, control group n = 6; Table 
1) under anti-cancer therapy. One experiment was done with serum from patients with 
stage IV gastric cancer (exercise group n = 6, control group n = 6; Supplemental Table S1), 
stage III/IV prostate cancer (exercise group n = 8, control group n = 10 [21]) or stage III/IV 
colorectal cancer (exercise group n = 6, control group n = 6 [21]). 
Table 1. Pre-intervention characteristics of the PC patient cohort. Values are given as mean (SD). 
Where appropriate, statistical analysis was done using independent samples t-test (a) or Mann–
Whitney test (b). 
Parameter 
Pancreatic Cancer (PC) 
P Control 
(n = 6) 
Resistance Exercise  
Using WB-EMS 
(n = 6) 
Sex   - 
Male, n (%) 3 (50%) 4 (60%)  
Female, n (%) 3 (50%) 2 (40%)  
Age (y) 61.0 ± 8.4 62.7 ± 9.1 0.748 a 
Figure 1. Resistance training using whole-body electromyostimulation (WB-EMS) and study flowchart. (A) The picture
displays a patient during a 20 min WB-EMS training session. The exercising person wore a vest, a hip belt, and upper-
arm and -thigh cuffs with integrated electrodes (for more details, please refer to [21]). Bipolar impulses simultaneously
addressed eight large muscle groups. (B) Study overview. The PC patients participated in our previous pilot study “Effects
of hole-body electromyostimulation c mbined with individualised nutritional support on body composition in patients
with advanced cancer: a controlled pilot trial” [20].
2.3. Patient Serum
Blood samples were collected at the beginning of the trial (pre), after 6 weeks of
intervention (mid) and at trial end after 12 weeks of intervention (post). The time between
the administration of chemotherapy and the blood collection was at least 3 days, except for
one exercising patient in whom chemotherapy was administered the day before the blood
collection at study entry. In the exercise group the blood withdrawal was done 60 min after
the training session using WB-EMS (mid and post). Blood samples were centrifuged and
serum and plasma were stored at −80 ◦C. For the in vitro study, we used serum from stage
III/IV pancreatic cancer patients (exercise group n = 6, control group n = 6; Table 1) under
anti-cancer therapy. One experiment was done with serum from patients with stage IV
gastric cancer (exercise group n = 6, control group n = 6; Supplemental Table S1), stage
III/IV prostate cancer (exercise group n = 8, control group n = 10 [21]) or stage III/IV
colorectal cancer (exercise group n = 6, control group n = 6 [21]).
Table 1. Pre-intervention characteristics of the PC patient cohort. Values are given as mean (SD).
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Age (y) 61.0 ± 8.4 62.7 ± 9.1 0.748 a
Tumor Stage (UICC) -
III, n (%) 1 (20%) 1 (20%)
IV, n (%) 5 (80%) 5 (80%)
Oncological Therapy -
Chemotherapy, n (%) 6 (100%) 6 (100%)
Other therapies, n (%) - -
Karnofsky Index (%) 78.3 ± 4.1 83.3 ± 10.3 0.178 b
6 min-Walking Distance (m) 557.5 ± 75.9 586.0 ± 54.5 (n = 5) 0.574 b
Body Parameters
Body Weight (kg) 74.6 ± 9.7 67.8 ± 6.9 0.193 a
Weight Lossin the last 3–6 month (%) 3.9 ± 5.1 9.0 ± 11.6 0.708 b
Body Mass Index (kg/m2) 25.6 ± 1.4 23.5 ± 2.5 0.093 a
Skeletal Muscle Mass (kg) 23.9 ± 6.7 22.0 ± 4.4 0.582 a
Blood Parameters
Albumin (g/L) 42.5 ± 2.2 40.9 ± 2.1 0.226 a
C-reactive Protein (mg/L) 19.7 ± 33.7 5.7 ± 3.3 0.335 a
Creatinine (mg/dL) 0.8 ± 0.1 0.8 ± 0.2 0.606 a
Hematocrit (%) 36.0 ± 2.1 37.8 ± 3.4 0.283 a
Hemoglobin (g/dL) 12.2 ± 0.8 12.7 ± 1.1 0.434 a
Leucocytes (×103/µL) 5.2 ± 2.3 5.5 ± 3.3 0.851 b
Erythrocytes (×106/µL) 3.9 ± 0.2 4.2 ± 0.3 0.143 b
Thrombocytes (×103/µL) 234.5 ± 133.4 181.2 ± 69.5 0.818 b
2.4. Cell Culture
All cells were cultivated in monolayers at 37 ◦C in 5% CO2 in a humidified incubator.
The human pancreatic ductal adenocarcinoma cell line Panc1 (Sigma-Aldrich, Munich, Ger-
many) was cultured in DMEM (Gibco, Thermo-Fisher Scientific, Waltham, MA, USA), 10%
FCS Superior (Merck KGaA, Darmstadt, Germany) and 100 IU/mL penicillin/100 µg/mL
streptomycin (Gibco). The cells (RRID: CVCL_0480) were kept in culture for no longer than
30 passages. The human pancreatic ductal adenocarcinoma cell line HPAC (ATCC #2119
(LGC Standards GmbH, Wesel, Germany)) was maintained in Ham F12 (Gibco), 10% FCS
Superior and penicillin/streptomycin (RRID: CVCL_3517; cells were kept in culture for no
longer than 30 passages). The murine pancreatic cancer cell line TB32047 was cultured in
DMEM, 10% FCS Superior and penicillin/streptomycin (RRID: CVCL_3517; kept in culture
for up to 30 passages). The human pancreatic ductal adenocarcinoma cells PaCaDD119
were maintained in medium consisting of DMEM + 20% FCS (Invitrogen #A3160501,
Thermo-Fisher) and keratinocyte serum-free medium and supplements (Thermo-Fisher,
mixing ration 2:1, plus penicillin/streptomycin (RRID: CVCL_1848; kept in culture for up
to 20 passages) [23]. The human pancreatic ductal adenocarcinoma PC cells Mayo4636
were cultured in Hepes-buffered DMEM/Ham F12, 10% FCS (HycloneTM #SH30084.03,
GE Healthcare, Chicago, IL, USA) and penicillin/streptomycin (cells were kept in culture
for no longer than 20 passages) [24]. The human pancreatic ductal adenocarcinoma PC
cells TKCC10 (squamous subtype) were maintained as described in Hardie et al. and kept
in culture for up to 20 passages [25,26]. The human pancreatic duct epithelial cells HPDE
were cultured in keratinocyte serum-free medium and supplements (RRID: CVCL_4376;
kept in culture for up to 20 passages). The human embryonic kidney cell line HEK293T
was provided by Dr. A. Kremer (Medical Department 1, Friedrich-Alexander University
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Erlangen-Nürnberg, Erlangen, Germany) and were cultured in DMEM, 10% FCS Superior
and penicillin/streptomycin (RRID: CVCL_0045; cells were kept in culture for no longer
than 30 passages). The murine embryonic fibroblasts 3T3L1 (Sigma-Aldrich) were main-
tained in DMEM, 10% FCS Superior and penicillin/streptomycin (RRID: CVCL_0123; kept
in culture for up to 10 passages). Primary human skeletal muscle myoblasts (HSMMs)
were purchased from Lonza (Basel, Switzerland) and cultured according to manufacturer’s
protocol. The murine myoblast cell line C2C12 (DSMZ, Braunschweig, Germany) was
cultured in DMEM, 10% FCS Superior and penicillin/streptomycin (RRID: CVCL_0188;
kept in culture for up to 15 passages). All cell cultures were mycoplasma-free.
2.5. Human Cancer Cell Growth and Apoptosis Assays
3–5 × 103/well or 2.5–3 × 104/well PC cells (Panc1, HPAC, PaCaDD119, Mayo4636,
TKCC10), non-malignant pancreatic cells (HPDE) or non-tumour control cells (HEK293T,
3T3L1) were plated into 96-well or 48-well plates, respectively, and after overnight incuba-
tion, cells (except of HPDE) were serum-deprived (0.1% FCS) for 18–24 h. Then, cells were
stimulated with medium containing 10% patient serum, with EPS-conditioned medium
from differentiated myotubes (DMEM/2% FCS plus 10% human serum from healthy indi-
viduals) or with recombinant proteins for 24–96 h. Determination of cell growth, apoptosis
and viability (BrdU incorporation, total cell number, number of apoptotic cells, DNA frag-
mentation) was done as described earlier [21]. Of note, the growth response of the tested
PC and non-malignant cells did not differ when cultured with human pre-intervention
serum compared to bovine serum.
2.6. Colony Formation Assay
An amount of 1.2–2.5 × 103/well PC cells (Panc1, PaCaDD119) were seeded into
12-well plates and after overnight incubation, cells were stimulated with medium contain-
ing 2–5% FCS with or without recombinant proteins for 7–10 d. Medium was changed
every other day. After fixation and staining of the cells with 0.2% crystal violet, colony
formation was determined by counting of colonies (n cells > 50). Pictures were taken
with the EZ4W stereo microscope (Leica, Wetzlar, Germany) with identical settings (20×
magnification, illumination intensity of 3). Images were processed using Photoshop CS5
(Adobe Inc., San Jose, CA, USA; sizing, contrast and brightness adjustment with identical
settings for image acquisition of all samples in a given experiment). Additionally, optical
density (590 nm) was measured after extraction of the stain using 10% acetic acid.
2.7. Scratch Wounding Assay
1.2 × 103 Panc1 cells per well were seeded into 48-well plates and cultivated until they
reached at least 95% confluency. Then, cells were serum-deprived for 18 h. Scratch wound-
ing was done using a 100 µL pipette tip and cells were stimulated either with medium
containing 10% serum from WB-EMS or control patients, or with medium containing 5%
FCS with or without recombinant proteins. Pictures of the wound were taken directly after
scratching (0 h) and after 24 h using the EVOS digital inverted microscope (AMG, Mill
Creek, WA, USA) with a 4-fold magnification and 40% brightness. Images were processed
using Photoshop CS5 (sizing, contrast and brightness adjustment with identical settings
for all samples in a given experiment). The width of the scratch wound (six measurements
along the scratch per picture) was quantified using ImageJ software (National Institute of
Health, Bethesda, MD, USA; SCR_003070).
2.8. Electric Pulse Stimulation
1.5 × 105/well primary human skeletal muscle myoblasts (HSMMs) or 2.5 × 105/well
murine myoblasts (C2C12) were seeded in 6-well plates. After reaching 70–90% confluency,
HSMMs or C2C12 myoblasts, were incubated for 3–4 d with DMEM/Ham F12 (Gibco) or
DMEM, respectively, both supplemented with 2% HycloneTM horse serum (GE Health-
care, Chicago, IL, USA) for in vitro differentiation into myotubes. Effective myogenic
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differentiation was verified by the grade of myoblast fusion and myogenin expression.
Electric pulse stimulation was performed with differentiated myotubes as described in
Schwappacher et al. [21]. EPS efficiency was examined via quantitative RT-PCR (mRNA
expression of CXCL5, PPARGC1A and MSTN).
2.9. Quantitative Reverse Transcription PCR (qRT-PCR)
Total RNA was isolated from cells using QIAzol® reagent (Qiagen, Venlo,
The Netherlands) according to manufacturer’s instructions. 0.5–1 µg was transcribed
into cDNA using the iScriptTM synthesis kit (Bio-Rad, Hercules, CA, USA). Quantita-
tive RT-PCR was performed using the CFX Connect Real-Time System and CFX Man-
ager software (Bio-Rad). The reference genes hypoxanthine phosphoribosyltransferase 1
(HPRT1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and/or ribosomal protein
lateral stalk subunit P0 (RPLP0) were used to calculate relative mRNA levels with the
2−∆∆CT method.
2.10. Primer Sequences
Oligonucleotide synthesis was done by Metabion International AG (Planegg, Ger-
many). For information about primer sequences for the analysis of EPS efficiency, and
the expression of myokines and exercise/myokine-responsive genes please refer to
Schwappacher et al. [21]. Additionally, the following primers were used: human IL10
(QT00041685, Qiagen); human CXCL1 (f) 5′-GTCCGTGGCCACTGAACTG-3′ and (r) 5′-
GGGGATGCAGGATTGAGGC-3′; human CCL4 (QT01008070, Qiagen); human FNDC5
(f) 5′-TGCACTCAGAGGGATGACTG-3′ and (r) 5′-CTTCTTGCAAGGCTGGAAAC-3′;
human SPARC (f) 5′-GAGATAGACCCAGCCCAGAG-3′ and (r) 5′-AGAAGATCCAGG-
CCCTCATG-3′.
2.11. Cytokine Array
For simultaneous detection of cytokines/myokines in the pre- and post-intervention
plasma pools of exercising (n = 6) and non-exercising control patients (n = 6) with ad-
vanced PC, a Human Cytokine Antibody Array (80 targets; Abcam, Cambridge, UK)
was carried out. The assay was conducted according to manufacturer’s instructions. The
Amersham 600 Imager (General Electric, Pittsburgh, PA, USA) was used for chemilumines-
cence detection. Signals were analysed with ImageJ software. Normalisation of the raw
densitometry data was done according to manufacturer’s recommendations. The mean
density of the negative controls (background) was subtracted from the density of each
cytokine spot; afterwards, the values were normalised to the mean positive control signal
(for each membrane). The values of the pre-intervention plasma pools from both patient
groups were compared and the cytokines with a difference of <20% in these values were
selected. Then, the ratios between the values of pre- and post-intervention plasma pools
within each patient cohort were determined. Additionally, the ratios between the values
of the post-intervention plasma pools of both patient groups were calculated. Differences
of >20% were considered significant and the respective cytokines were subjected to fur-
ther analysis. For details regarding the cytokine array with medium from untreated or
EPS-treated primary human myotubes please refer to Schwappacher et al. [21]. For the
normalised densitometry data please refer to the Supplemental Tables S2 and S3.
2.12. Cytokine Enzyme-Linked Immunosorbent Assay (ELISA)
For measurement of human CXCL1/Groα and human CCL4/Mip1β in the plasma of
non-exercising and exercising PC patients, DuoSet ELISA (R & D Systems, Minneapolis,
MN, USA) was used according to manufacturer’s instructions. Measurement of human
IL10 was performed with Ready-SET-Go! ELISA (Invitrogen, Carlsbad, CA, USA) according
to manufacturer’s protocol. For each cytokine the ELISA analysis was done twice.
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2.13. Immunoblotting
0.6–1 × 105/well PC cells (Panc1, PaCaDD119) were seeded into 12-well plates and
after overnight incubation, cells were serum-starved for 18–24 h. Cells were treated with
medium containing 20 ng/mL CXCL1, IL10 and CCL4 or BSA as control for 48–72 h. Cells
were lysed in cell lysis buffer (0.5% IGEPAL® CA-630, 150 mM NaCl, 20 mM Tris pH 7.4,
protease inhibitors (Protease Inhibitor Cocktail Set I, Calbiochem, Merck KGaA), 10 mM
phenylmethylsulfonyl fluoride and phosphatase inhibitors (PhosSTOP, Roche Diagnos-
tics, Penzberg, Germany). Separation of the cell extracts was done by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis. Immunoblotting was carried out with
the polyclonal rabbit antibody specific for poly(ADP-ribose) polymerase (PARP; full length,
116 kDa and cleaved PARP large fragment, 89 kDa; Cell Signaling Technologies, Danvers,
MA, USA; dilution 1:1000; RRID:AB_2160739). Additionally, the cell extracts were ex-
amined by immunoblotting using the monoclonal rabbit antibodies specific for caspase
3 and 7 (both from Cell Signaling Technologies; dilution 1:2000; RRID: AB_2798429, RRID:
AB_2687912) and the monoclonal mouse antibody against α-actin (Santa Cruz Biotechnol-
ogy, Dallas, TX, USA; dilution 1:5000; RRID: AB_626632). The membranes (Immobilon-P
Membrane, PVDF, 0.45 µm, Merck KGaA) were analysed with the Amersham 600 Imager
using horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) and enhanced chemiluminescence (Clarity Western
ECL Substrate, Bio-Rad). The signals were quantified with ImageJ software.
2.14. Statistical Analysis
Study group differences at baseline in Table 1 and Supplemental Table S1 were exam-
ined by independent samples t-test or Mann–Whitney test. Statistical analysis for body
weight, body mass index and skeletal muscle mass in Figure 2 was performed by paired
t-test (post vs. pre, within the exercise group) and Student’s t-test (post, between the
groups); statistical analysis for Karnofsky index and 6 min-walking test was done using
Wilcoxon signed-rank test (post vs. pre, within the exercise group) and Mann–Whitney
test (post, between the groups). For statistical analysis of BrdU uptake, DNA fragmen-
tation and gene expression after stimulation with patient serum, two-tailed paired t-test
(post vs. pre, within a patient group) or Student’s t-test (post, between the groups) were
applied. For evaluation of cell counting, Trypan blue exclusion experiments and scratch-
wounding assays, Wilcoxon signed-rank test (post vs. pre, within a patient group) and
Mann–Whitney test (post, between the groups) were used. Student’s t-test was applied
for data analysis of BrdU incorporation, DNA fragmentation, gene expression, protein
expression (immunoblot densitometry) and OD measurement (colony formation) after
stimulation with EPS-conditioned myotube medium or with recombinant proteins. Cell
counting, numbers of colonies (colony formation) experiments and scratch-wounding
assays after treatment with EPS medium or recombinant proteins were evaluated using
Mann–Whitney test. Graphs depict the mean (SD). The respective number of experiments
is stated in the Figure legends. Statistical analysis was performed using GraphPad Prism
8.1.2 (GraphPad Software, San Diego, CA, USA; RRID: SCR_002798). p values of <0.05
were considered statistically significant.
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by very weak patients. The exercise intervention was combined with a high-protein diet 
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3. Results
3.1. t esi a atie t ata
I r er t erfor a deeper assessment of the anti-cancer effects of exercise on
tumour cells in advanced cancer disease, we used plasma/serum from patients with stage
III I [20]. Patients with advanced PC are very prone to develop cancer cachexia;
cachexia-induced muscle wasting strongly limits the physical performance of the affected
patients [27]. The study patients participated in a 12-week xercise training using WB-EMS
(2×/week, 20 min/session), a form of resistance exercise hich c rf r ed even
by very ea ti ts. rcis i t r ti as c bined ith a high-protein diet
accor i t t i t r ti l i li s f triti therapy. Figure 1 displays a patient
duri - tr i i t st fl c art (six PC patients with exercise, six non-
exercising PC patients as controls). Table 1 specifies the patients’ baseline d mographic and
disease characteristics. There w r no sig ifica t differences between th two study groups
regarding body parameters, dis ase-relat d weight loss, performanc status (Karnofsky
index) and physic l functioning (6 mi -walking distance). Blood parameters did not
significantly differ; of note, two of the c ntrol patients had a substantially higher blood
level of C-reactive protein at trial entry.
e si l t t ll r l ara eters i proved or at least stabilised
in t e r i t i i r after the intervention period of 12 weeks (Figure 2).
Perfor ance i l f ti i r i the exercising patients (Karnofsky index:
pre 83.3 ( ) 10.3% (SD), post 8. 3 9.83 , Figure 2D; 6 min-walking distance:
pre . ± 54. 8 m, post 601.4 ± 60.25 m, Figure 2E), i t t t the non-exercising
controls (Karnofsky index: pre 78.3 ± 4.08%, post 80.0 ± 8.94%; 6-min-walki g dista ce: pre
557.5± 75.88 m, post 543.7± 62.95 m). Body weight (pre 67.83 ± 6.92 kg, post 68.23 7.35 kg,
Figure 2A), body mass index (pre 23.46 ± 2.50 kg/m2, post .62 ± 2.82 kg/m2, Figure 2B)
and skeletal muscle mass (pre 22.04 ± 4.38 kg, post 21.95 ± 4.18 kg, Figure 2C) remained
stable in the exercising patients during the 12 week intervention; however, these parameters
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deteriorated in the non-exercising control group (body weight: pre 74.63 ± 9.73 kg, post
72.37 ± 10.38; body mass index: pre 25.62 ± 1.36 kg/m2, post 24.81 ± 1.25 kg/m2; skeletal
muscle mass: pre 23.90 ± 6.73 kg, post 23.32 ± 6.53 kg). Yet, the number of patients per
group was too small in order to reach statistical significance.
3.2. Exercise Stimuli Affect PC Cell Growth and Viability
90% of PC patients are diagnosed with a pancreatic ductal adenocarcinoma, a very
lethal form of cancer where effective therapies are lacking [28]. We stimulated the human
pancreatic ductal adenocarcinoma cell lines Panc1 and HPAC, and the murine pancreatic
cancer cell line TB32047 with pre- and post-intervention serum (collected after 12 weeks)
of advanced PC patients with (n = 6) or without WB-EMS-mediated resistance exercise
(n = 6) for 96 h. PC cell growth was significantly inhibited by the exercise serum pool, while
non-malignant cells were unaffected (Figure 3A: Panc1, −8.53%, p = 0.027 (Ex pre 0.998
(mean) ± 0.115 (SD), Ex post 0.913 ± 0.129, Ctl pre 1.00 ± 0.133, Ctl post 0.982 ± 0.064);
HPAC,−8.83%, p = 0.018 (Ex pre 0.89± 0.023, Ex post 0.811± 0.017, Ctl pre 1.00± 0.284, Ctl
post 0.988± 0.099; TB32047,−10.33%, p = 0.0113 (Ex pre 1.101± 0.108, Ex post 0.902± 0.114,
Ctl pre 1.00 ± 0.182, Ctl post 0.988 ± 0.092; Figure 3C: Panc1, −18.56%, p = 0.0078 (Ex pre
48.5 ± 5.95, Ex post 39.5 ± 7.16, Ctl pre 44.38 ± 5.5, Ctl post 48.19 ± 6.97; for additional
statistical analysis, please refer to the legend of Figure 3). The anti-tumour effects of
serum from exercising patients occurred in both, human and murine PC cells. A patient
serum pool (n = 4) collected mid-exercise-intervention (after 6 weeks) also significantly
decreased PC cell proliferation (Figure 3A, grey circles/black squares, Panc1, −5.72%,
p = 0.0214 (Ex pre 0.985 ± 0.055, Ex post 0.929 ± 0.062, Ctl pre 1.00 ± 0.095, Ctl post
1.00 ± 0.071), indicating that the anti-cancer impact of resistance exercise using WB-EMS
became effective already after a shorter training period. Furthermore, the incubation of
PC cells with exercise serum pools from patients with other advanced-stage carcinomas,
e.g., of the stomach, the colon/rectum or the prostate also significantly attenuated PC
cell growth (Figure 3B; gastric, n = 6, −7.42%, p = 0.0153 (Ex pre 0.959 ± 0.08, Ex post
0.888± 0.087, Ctl pre 1.00± 0.063, Ctl post 1.03± 0.07); colorectal, n = 6,−16.6%, p = 0.0247
(Ex pre 0.842 ± 0.064, Ex post 0.702 ± 0.126, Ctl pre 1.00 ± 0.181, Ctl post 1.03 ± 0.059);
prostate, n = 8, −11.23%, p = 0.0498 (Ex pre 0.884 ± 0.156, Ex post 0.785 ± 0.202, Ctl pre
1.00 ± 0.126, Ctl post 0.974 ± 0.048); for additional statistical analysis, please refer to the
legend of Figure 3; for patient characteristics please refer to the Supplemental Table S1 and
Schwappacher et al. [21]). These findings imply a general anti-tumour effect of exercise-
conditioned serum, independent from the tumour entity in the donor patients. Importantly,
neither human nor murine non-malignant cells were influenced by the exercise serum
(Figure 3A,B; for statistical data, please refer to the legend of Figure 3). We could further
demonstrate that PC cells undergo increased cell death when incubated with exercise-
trained patient serum (Figure 3D, trypan blue exclusion, +71.36%, p = 0.0313 (Ex pre
5.89± 3.91%, Ex post 10.09± 4.51%, Ctl pre 6.69± 4.86%, Ctl post 5.53± 2.81%); Figure 3E,
DNA fragmentation, +30.81%, p = 0.0667 (Ex pre 0.868 ± 0.151, Ex post 1.136 ± 0.132, Ctl
pre 1.00 ± 0.251, Ctl post 0.701 ± 0.221)). This is an important finding as deregulation of
apoptosis is a general mechanism of pancreatic ductal adenocarcinoma cells to ensure their
own survival.
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Then, the cells were stimulated for 96 h with 10% serum from stage III/IV PC patients taken at study entry (pre), after
a 6-week (mid) or after a 12-week (post) WB-EMS resistance exercise regimen (control group, Ctl; exercising group, Ex).
Cell proliferation was measured and is shown relative to the values after stimulation with a pre-intervention serum pool
from control patients (n = 6). The graph depicts the mean (SD); number of independent experiments and passage number
(p#) at which the experiments were performed: Panc1 n = 4 (p# 2–17), HPAC n = 3 (p# 3–14), 293T n = 3 (p# 21–29), Panc1
(mid) n = 4 (p# 2–18), TB32047 n = 6 (p# 5–14), 3T3L1 n = 4 (p# 2–10). p values for non-malignant control cells upon exercise
serum post vs. pre: 293T p = 0.0656 (Ex pre 1.038 ± 0.08, Ex post 1.112 ± 0.046, Ctl pre 1.00 ± 0.086, Ctl post 1.088 ± 0.069),
3T3L1 p = 0.7018 (Ex pre 0.994 ± 0.13, Ex post 0.965 ± 0.078, Ctl pre 1.00 ± 0.123, Ctl post 0.996 ± 0.041). (B) Panc1 and
non-malignant cells were serum-starved and incubated for 96 h with pre- and post-intervention serum pools from exercising
or control patients with advanced gastric (Ex n = 6, Ctl n = 6), colorectal (Ex n = 6, Ctl n = 6) or prostate tumours (Ex n = 8,
Ctl n = 10). Then, BrdU incorporation was measured. Additional statistical analysis of the effects of post-intervention sera of
exercising vs. control patients on Panc1 cells: gastric p = 0.0486; colorectal p = 0.0034; prostate p = 0.0498. Statistical analysis
of pre- vs. post-exercise serum incubation on 293T cells: gastric p = 0.6824 (Ex pre 1.011 ± 0.118, Ex post 1.037 ± 0.209,
Ctl pre 1.00 ± 0.196, Ctl post 1.064 ± 0.117); colorectal p = 0.5426 (Ex pre 0.947 ± 0.033, Ex post 0.933 ± 0.028, Ctl pre
1.00 ± 0.136, Ctl post 0.983 ± 0.035); prostate p = 0.6026 (Ex pre 1.022 ± 0.054, Ex post 1.044 ± 0.072, Ctl pre 1.00 ± 0.119, Ctl
post 0.973 ± 0.086). Mean (SD); number of independent experiments and passage number: gastric Panc1 n = 4 (p# 2–15),
293T n = 3 (p# 10–21); colorectal Panc1 n = 4 (p# 20–28), 293T n = 4 (p# 11–20); prostate Panc1 n = 4 (p# 3–17), 293T n = 3 (p#
12–21). (C,D) Starved Panc1 were treated with serum pools from exercising or control PC patients. After 96 h, cell viability
was examined by determination of total cell numbers ((C); numbers per mL × 104; 8 independent experiments, p# 3–12)
and the number of apoptotic/dead cells ((D); % of total cell number; additional statistical analysis between the groups
after post-intervention serum incubation, p = 0.0649; mean (SD), 6 independent experiments, p# 3–12). (E) Apoptotic DNA
fragmentation in Panc1 cells was determined after 48 h of treatment with exercise serum (shown relative to pre-intervention
control serum values; additional statistical analysis between the groups after post-intervention serum incubation, p = 0.0147).
Mean (SD) of 4 independent experiments, p# 3–16. (F) PC cells (Panc1, HPAC, PaCaDD119, TB32047) and non-malignant
cells (HEK293T, 3T3L1) were serum-starved and treated with EPS-conditioned medium from in vitro-differentiated human
or murine myotubes for 48 h, and cell proliferation was measured. The graph displays the relative proliferation of untreated
cells as 0%, and the percentage difference in proliferation after treatment with EPS-conditioned compared to unconditioned
medium. p values for non-cancer control cells (293T) treated vs. untreated: p = 0.6044; 3T3L1, p = 0.0377. Mean (SD),
number of independent experiments and passage number: Panc1 n = 8 (p# 20–29), HPAC n = 7 (p# 18–27), PaCaDD119
n = 8 (p# 2–18), 293T n = 10 (p# 11–21), TB32047 n = 8 (p# 19–27), 3T3L1 n = 6 (p# 13–20). (G) The effects of EPS-conditioned
human myotube medium on total (per mL × 104) and apoptotic/dead Panc1 cell numbers were measured. Mean (SD) of
9 independent experiments. (H) Relative cell death of Panc1 and PaCaDD119 after incubation with EPS-conditioned human
myotube medium for 24–48 h was determined; mean (SD), number of independent experiments and passage number: Panc1
n = 16 (p# 2–13), PaCaDD119 n = 6 (p# 11–19). * p < 0.05, ** p < 0.01, *** p < 0.001; paired two-tailed t-test and Student’s t-test
in (A,B,E); Student’s t-test in (F,H); Wilcoxon signed-rank and Mann–Whitney test in (C,D,G).
Electric pulse stimulation (EPS) of cultured skeletal muscle cells at the myotube stage
can be used as an in vitro model of exercise [29,30]. Consistent with the observed effects of
patient serum after WB-EMS-mediated resistance exercise, we found that EPS-conditioned
medium from human or murine myotubes decreased proliferation of human and murine
PC cells (Panc1, −6.91 ± 4.83% p = 0.0401; HPAC, −9.03 ± 6.1%, p = 0.0384; PaCaDD119,
−12.16 ± 8.62%, p = 0.0424; TB32047, −11.48 ± 6.34%, p = 0.0002), while growth of non-
malignant cells was not inhibited (293T, +5.54 ± 10.19%; 3T3L1, +5.5 ± 5.52; Figure 3F).
The number of PC cells was also significantly reduced upon incubation with EPS medium
(Panc1, −14.35%, p = 0.0171 (untreated 24.0 ± 2.81, 2× 20 min 20.56 ± 2.64), Figure 3G,
left bars), while cell death, quantified by apoptotic/dead cell numbers (Panc1, +53.59%,
p = 0.042 (untreated 15.31 ± 6.44%, 2× 20 min 23.52 ± 8.65%); Figure 3G, right bars)
and DNA fragmentation (Panc1, +14.35%, p = 0.0408 (untreated 1.00 ± 0.146, 2× 20 min
1.143 ± 0.269); PaCaDD119, +29.09%, p = 0.0065 (untreated 1.00 ± 0.167, 2× 20 min
1.291 ± 0.208); Figure 3H), was increased. Taken together, these results further substantiate
our previous conclusion that resistance exercise induces defensive humoral factors in
patients with advanced cancer disease that target malignant cell growth and viability, while
non-tumour cells are unaffected.
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3.3. Exercise-Induced Myokines Control PC Cell Proliferation
These data encouraged us to analyse the blood of exercise-trained cancer patients in
order to identify muscle-secreted factors, which might, at least partially, be responsible for
the anti-proliferative and pro-apoptotic impact of exercise-conditioned serum on cancer
cells. To determine myokines that are induced by resistance exercise using WB-EMS, we
performed a cytokine array with plasma pools from our advanced PC patients. The plasma
protein amount of the following six cytokines/myokines was substantially enhanced by
the 12-week exercise training (Table 2 and Supplemental Table S2): C-X-C motif ligand
1 (CXCL1; ratio post-intervention/pre-intervention 1.88), interleukin 10 (IL10; 1.52), C-C
motif chemokine ligand 4 (CCL4; 1.30), CCL22 (1.37), lymphotoxin α (LTA; 1.23), and
angiogenin (1.21). Due to its well-known angiogenic character on cancer cells, we excluded
angiogenin from our current research. In addition to increased myokine expression of
e.g., IL6, brain-derived neutrophic factor (BDNF), and vascular endothelial growth factor
(VEGF), as previously described [21], CXCL1, IL10, and CCL4 protein levels were also
upregulated in the medium of human primary myotubes after EPS treatment (Table 3
and Supplemental Table S3; CXCL1 (ratio EPS-treated/untreated 3.36), IL10 (1.43), CCL4
(1.19)). However, we could not detect an increase in CCL22 and LTA protein amount in
the myotube media as found in patient plasma after exercise, pointing towards either
a non-muscle origin of these two protein factors, or an exercise-independent regulation.
Since we investigated a plasma pool, patient-specific factors, such as medication, might be
responsible for the induction of CCL22 and LTA in the exercise-trained serum pool. Apart
from that, our results strongly suggest that CXCL1, IL10 and CCL4 are muscle-derived
factors and that their expression and/or their release from skeletal muscle are enhanced
by WB-EMS-mediated resistance training. We could also confirm a higher concentration
of CXCL1, IL10 and CCL4 proteins in patient plasma after exercise via ELISA assays
(Figure 4A). According to the literature, CXCL1, IL10 and CCL4 are more or less well
described myokines, but as muscle-derived factors no significant anti-cancer effect has
been attributed to them yet [2,30–33].
Table 2. Potential myokines in conditioned plasma from advanced-stage PC patients after WB-EMS-
mediated resistance exercise. For simultaneous detection of cytokines/myokines in the pre- and
post-intervention plasma pools of exercise-trained (n = 6) or non-exercising control patients (n = 6), a
cytokine array was performed. For details regarding the determination of the presented changes,
please refer to Material and Methods. Differences between the signal intensities of >20% were
considered significant and the respective cytokines/myokines were subjected to further analysis.
Target Control Exercise Ratio Post-Intervention
pre post pre post Ctl Ex
CXCL1 (Groα) 1.00 1.05 1.00 1.88 1.00 1.59
IL10 1.00 0.69 1.00 1.52 1.00 1.86
CCL4 (Mip1β) 1.00 0.84 1.00 1.30 1.00 1.54
CCL22 (MDC) 1.00 0.97 1.00 1.37 1.00 1.47
LTA (TNFβ) 1.00 0.74 1.00 1.23 1.00 1.36
Table 3. Exercise-mimicking EPS induces CXCL1, IL10 and CCL4 in vitro. Primary human myotubes
were treated with EPS (based on WB-EMS training parameters) and a serum pool from 3 independent
EPS treatments was used for a cytokine array. The change in protein expression of the identified
exercise-induced cytokines (please see Table 2) in EPS-conditioned vs. unconditioned myotube
medium is shown.
Target Untreated 2× 20 min EPS
CXCL1 (Groα) 1.00 3.36
IL10 1.00 1.43
CCL4 (Mip1β) 1.00 1.19
CCL22 (MDC) 1.00 0.86
LTA (TNFβ) 1.00 0.84
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Figure 4. A set of exercise-induced myokines regulates growth behaviour of PC cells. (A) ELISA-based measurements of
CXCL1, IL10 and CCL4 blood levels using plasma from control and exercise-trained patients with advanced PC. Absorbance
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values are shown relative to the pre-intervention plasma in both patient groups. For some patients a measurement was
not possible due to detection sensitivity: CXCL1, control patients 5 out of 6 (5/6) and exercising patients 4/6; IL10, control
patients 6/6 and exercising patients 6/6; CCL4, control patients 5/6 and exercising patients 3/6. Mean (SD) of 2 independent
experiments. (B) Gene expression analysis in EPS-treated human myotubes shows the induction of CXCL1, IL10 and CCL4
as well as of established myokines (IL6, FNDC5/irisin, SPARC, BDNF and IL15). Known EPS marker genes (CXCL5,
PPARGC1A and MSTN) are regulated accordingly. The graph depicts the fold changes relative to the values from untreated
myotubes. Mean (SD); number of independent experiments: CXCL1 n = 10, IL10 n = 6, CCL4 n = 7, IL6 n = 10, FNDC5 n = 11,
SPARC n = 12, BDNF n = 7, IL15 n = 6, CXCL5 n = 8, PPARGC1A n = 10, MSTN n = 10; passage number 2–6. (C) Panc1 cells
were serum-starved and stimulated with increasing concentrations (1, 2, 5, 10 or 20 ng/mL) of recombinant human CXCL1
(left), human IL10 (middle left), human CCL4 (middle right) or with a combination of them (right) for 24 h. Cell proliferation
was measured and is shown relative to the values after treatment without a recombinant protein (set as 0%). Mean (SD),
number of independent experiments: CXCL1 n = 6, IL10 n = 7, CCL4 n = 6, combi n = 9; passage number 2–17. Additional
statistics: CXCL1: 5 ng/mL p = 0.0105, 10 ng/mL p = 0.0038; IL10: 1 ng/mL p = 0.0075, 2 ng/mL p = 0.0033, 5 ng/mL
p = 0.0008, 10 ng/mL p < 0.0001; CCL4: 5 ng/mL p = 0.0053, 10 ng/mL p = 0.0182; combi: 5 ng/mL p = 0.0004, 10 ng/mL
p = 0.0001. (D) Different PC cells (Panc1, PaCaDD119, Mayo4636, TKCC10) and non-cancer pancreatic cells (HPDE) were
serum-starved (except of HPDE) and treated with 20 ng/mL of CXCL1, IL10, CCL4, CCL22 or LTA for 24–48 h. Then, BrdU
uptake was measured. The graphs depict cell proliferation relative to untreated cells (set as 0%). Prolonged starvation
(or the addition of 20 ng/mL tumour necrosis factor α for HPDE) and normal growth conditions were used as negative
and positive proliferation control, respectively. Mean (SD), number of independent experiments and passage number (p#):
Panc1, CXCL1 n = 10, IL10 n = 10, CCL4 n = 10, CCL22 n = 10, LTA n = 5, p# 5–18; PaCaDD119, CXCL1 n = 4, IL10 n = 5,
CCL4 n = 3, CCL22 n = 4, LTA n = 4, p# 3–8; Mayo4636, CXCL1 n = 6, IL10 n = 6, CCL4 n = 5, CCL22 n = 3, LTA n = 3, p#
6–18; TKCC10, CXCL1 n = 6, IL10 n = 5, CCL4 n = 5, CCL22 n = 5, LTA n = 5, p# 3–13; HPDE, CXCL1 n = 4, IL10 n = 5, CCL4
n = 5, CCL22 n = 5, LTA n = 5, p# 7–19. Additional statistics: Panc1: CCL22 p = 0.3509, LTA p = 0.1937; PaCaDD119: CCL22
p = 0.2874, LTA p = 0.6950; Mayo4636: CCL22 p = 0.2834, LTA p = 0.4724; TKCC10: CCL22 p = 0.8115, LTA p = 0.6868; HPDE:
CXCL1 p = 0.7823, IL10 p = 0.6707, CCL4 p = 0.7119, CCL22 p = 0.6737, LTA p = 0.7499. (E) Panc1 and PaCaDD119 were
stimulated with a combination of CXCL1, IL10 and CCL4 (20 ng/mL each) for 7–10 d, and colony formation was determined.
After staining the cells with crystal violet, images were taken using the EZ4W stereo microscope with identical settings, and
colonies were counted from random sections of each well. Images were processed using Photoshop (Adobe; sizing, contrast
and brightness adjustment with identical settings for image acquisition of all samples in a given experiment); scale bar,
500 µm. Additionally, the stain was extracted, and the OD was measured (590 nm). Mean (SD), number of independent
experiments and passage number: Panc1 count n = 6, absorbance n = 6, p# 2–12; PaCaDD119 count n = 8, absorbance n = 10,
p# 11–18. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; Student’s t-test in B–D; Student’s t-test and Mann–Whitney test
in (E).
To consolidate our protein data from the cytokine arrays and the ELISA measurements,
we performed gene expression experiments in human primary myotubes after in vitro
exercise mediated by EPS. We found that the mRNA amount of CXCL1, IL10 and CCL4 was
increased upon EPS (CXCL1, 8.95-fold ± 3.35, p < 0.0001; IL10, 1.81 fold ± 0.55, p < 0.0001;
CCL4, 3.42 fold ± 1.64, p < 0.0001; Figure 4B). To strengthen our exercise-mimicking EPS
approach, we included the expression analysis of known EPS-responsive markers and
established myokines. CXCL5 (8.91 fold ± 5.94, p < 0.0001), PPARGC1A (peroxisome
proliferator-activated receptor γ coactivator 1α; 1.22 fold ± 0.28, p = 0.0003) and MSTN
(Myostatin; 0.76 fold± 0.11, p < 0.0001) are regulated in muscle cells by EPS, confirming our
previous results and data from the literature [21,34–40]. The myokines IL6 (5.8 fold ± 3.47,
p < 0.0001), FNDC5 (1.52 fold ± 0.58, p < 0.0001), SPARC (1.26 fold ± 0.46, p = 0.0053),
BDNF (1.54 fold ± 0.25, p < 0.0001) and IL15 (1.39 fold ± 0.34, p < 0.0001) are also induced
by our EPS protocol [30–32,35,40–42].
Since our data from the cytokine arrays and the gene expression analysis strongly
suggest that CXCL1, IL10 and CCL4 are induced in and released from skeletal muscle
in PC patients after resistance exercise, we checked their impact on PC cell growth and
viability. Dose response curves in Panc1 cells showed that recombinant human CXCL1,
IL10 and CCL4 exert a significant anti-proliferative effect already at concentrations between
1 to 5 ng/mL, with the strongest effect at 20 ng/mL (CXCL1, −9.36 ± 5.97%, p = 0.0037;
IL10, −8.26± 5.32%, p = 0.0017; CCL4, −7.56± 2.41%, p < 0.0001; Figure 4C). The combina-
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tion of the three myokines showed a synergistic effect with a suppression of Panc1 prolifera-
tion of more than 16% upon the incubation with 20 ng/mL of each protein (−16.72± 7.60%,
p < 0.001; Figure 4C, right graph; for additional statistical analysis, please refer to the
legend of Figure 4). Furthermore, we could show that the stimulation of different PC cells
with 20 ng/mL of CXCL1, IL10 or CCL4 significantly decreased their proliferation, while
the non-malignant pancreatic cells HPDE were unaffected (CXCL1: Panc1 −8.50 ± 6.6%,
p < 0.0001; PaCaDD119 −6.86 ± 2.92%, p = 0.0009; Mayo4636 −5.52 ± 4.2%, p = 0.0092;
TKCC10 −5.25 ± 2.1%, p < 0.0001; IL10: Panc1 −9.27 ± 7.32%, p < 0.0001; PaCaDD119
−8.94 ± 4.48%, p = 0.0017; Mayo4636 −6.31 ± 4.8%, p = 0.0091; TKCC10 −7.73 ± 7.97%,
p = 0.0396; CCL4: Panc1 −6.69 ± 10.87%, p = 0.0245; PaCaDD119 −7.21 ± 4.08%, p = 0.0066;
Mayo4636 −5.19 ± 2.02%, p < 0.0001; TKCC10 −5.24 ± 4.14%, p = 0.012; Figure 4D).
As additional controls, we examined the effect of recombinant human CCL22 and LTA,
proteins which were increased in the plasma of PC patients doing exercise but not in the
EPS myotube medium (please see Tables 2 and 3), but found no significant suppressive
effect on PC cell growth (Figure 4D). We also tested the impact of CXCL1/IL10/CCL4
on the colony forming ability of PC cells (Figure 4E); this in vitro technique examines
the capability of tumour cells to form large colonies. We found that PC colony forma-
tion was significantly suppressed by the myokine mix (Panc1: counting −49% (untreated
13.26 ± 2.74, Myokine combi 6.77 ± 4.3), p = 0.0317; OD −24.17% (untreated 1.00 ± 0.35,
Myokine combi 0.76± 0.2), p = 0.013; PaCaDD119: counting−34.83% (untreated 7.45± 0.99,
Myokine combi 4.85 ± 1.12), p = 0.0003; OD −19.18% (untreated 1.00 ± 0.19, Myokine
combi 0.81 ± 0.11), p < 0.0001; Figure 4E), further consolidating our hypothesis that muscle-
derived CXCL1, IL10 and CCL4 are regulators of PC cell growth.
3.4. Myokine-Mediated Regulation of PC Cell Migration
In addition, we checked for effects of CXCL1, IL10 and CCL4 on the mobility of PC
cells using the scratch wound healing assay. Firstly, Panc1 cells were treated with pre- or
post-intervention serum from advanced PC patients for 24 h. As shown in Figure 5A, the
wound closure over the scratch of Panc1 cells was significantly reduced after stimulation
with exercise-conditioned serum compared to pre-intervention serum from the exercise
group and serum from the controls (Ctl: pre 42.14 ± 9.94%, post 40.83 ± 11.53%; Ex:
pre 38.78 ± 12.66%, post 18.82 ± 8.06%; Ex post vs. pre p = 0.0020; Ctl post vs. Ex post
p < 0.0001). When Panc1 cells were treated with a combination of CXCL1, IL10 and CCL4
for 24 h, the wound healing over the scratch was also significantly decreased (Figure 5B).
The analysis revealed that the wound of untreated Panc1 cells has closed by 44.10 ± 9.19%
in contrast to myokine-stimulated cells, where only 33.09 ± 6.75% of the initial scratch
area was covered by cells (p = 0.0207; Figure 5B). The results suggest that CXCL1, IL10
and CCL4, which were induced by WB-EMS resistance exercise, decreased the mobility of
PC cells.
3.5. CXCL1, IL10 and CCL4 Induce PC Cell Death
In our previous study, a gene array from prostate cancer cells with cancer-associated
genes revealed that specific genes controlling cancer cell growth and death, are regulated
by resistance exercise using WB-EMS [21]. For the present report, we performed further
experiments in PC cells. We determined that the mRNA expression of CASP3 and 7 was
significantly upregulated after a 72 h treatment with exercise serum from advanced-stage
PC patients (post- vs. pre-exercise serum: CASP3, 1.28 fold ± 0.05, p = 0.043; CASP 7,
1.12 fold ± 0.15, p = 0.0118; post-intervention serum exercise vs. control group: CASP3,
p = 0.0034; CASP7, p = 0.0543, Figure 6A), as well as with EPS-conditioned myotube
medium (CASP3, 1.22 fold ± 0.12, p = 0.0396; CASP 7, 1.37 fold ± 0.17, p = 0.0206). Im-
portantly, PC cells treated with a combination of CXCL1/IL10/CCL4 for 48–72 h also
showed a significantly higher amount of CASP3 and CASP7 mRNA compared to untreated
cells (Panc1: CASP3, 1.84 fold ± 0.4, p = 0.0054; CASP 7, 1.74 fold ± 0.14, p < 0.0001;
PaCaDD119: CASP3, 1.53 fold ± 0.42, p = 0.0486; CASP 7, 2.13 fold ± 0.6, p = 0.0095;
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Figure 6A). Using immunoblot analysis, we could determine a moderate, yet apparent in-
crease in protein expression of caspase 3 (Panc1: +28.58% (untreated 1.31 ± 0.28, Myokine
combi 1.69 ± 0.23), p = 0.0502; PaCaDD119, +31.3% (untreated 0.70 ± 0.16, Myokine
combi 0.92 ± 0.16), p = 0.0624; immunoblot not shown) and caspase 7 (Panc1: +45.52%
(untreated 0.47 ± 0.12, Myokine combi 0.68 ± 0.06), p = 0.0531; PaCaDD119, +45.42%
(untreated 0.77 ± 0.17, Myokine combi 1.12 ± 0.19), p = 0.0144; Figure 6B). Furthermore,
we performed immunoblot analysis for the cleavage of the caspase 3/7 substrate PARP
on PC cell lysates after incubation with CXCL1/IL10/CCL4 for 48–72 h (Figure 6C). The
expression analysis showed a significant increase in PARP cleavage (Panc1: +32.4% (un-
treated 0.22 ± 0.02, Myokine combi 0.29 ± 0.02), p = 0.0172; PaCaDD119: +54.07% (un-
treated 0.17 ± 0.09, Myokine combi 0.31 ± 0.13), p = 0.0462; Figure 6C). Subsequent DNA
fragmentation analysis revealed that CXCL1, IL10 and CCL4 alone and, in a synergistic
manner, in combination induces the death of PC cells (Panc1: CXCL1, +21.44 ± 20.71%,
p = 0.0001; IL10, +12.20 ± 14.68%, p = 0.0014; CCL4, +9.15 ± 11.2%, p = 0.0016; combi-
nation, +42.04 ± 36.85%, p = 0.0067; Figure 6D; PaCaDD119: CXCL1, +24.23 ± 22.45%,
p = 0.0145; IL10, +23.67 ± 14.04%, p = 0.0011; CCL4, +26.14 ± 14.05%, p = 0.0005; combi-
nation, +48.48 ± 23.17%, p = 0.0016; Figure 6E). Treatment with CCL22 or LTA served as
additional controls and had no stimulatory effect on PC cell death (Figure 6D,E). Taken
together, our data show a myokine-induced upregulation of caspase 3 and 7 expression
and PARP cleavage, and an increase in PC cell apoptosis and death upon treatment with
CXCL1/IL10/CCL4.
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Figure 6. Apoptotic events are regulated by CXCL1, IL10 and CCL4 in PC cells. (A) Panc1 and PaCaDD119 cells were
serum-starved and sti ulate eit er it control or exercise-conditioned serum from advanced PC patients, with an
EPS-conditioned medium pool from human myotubes, or with a combination of CXCL1, IL10 and CL4 (20 ng/mL each)
for 48–72 h. Then, CASP3 and 7 mRNA xpression levels were analyse , and results are depicted in the graph as fold
changes to the respective control/untreated sample. Mean (SD), number of independent experiments and passage number
(p#): Panc1, CASP3, serum n = 4, EPS n = 3, Myokine combi n = 4, p# 7–15; Panc1, CASP7, serum n = 3, EPS n = 3, Myokine
combi n = 4, p# 8–17; PaCaDD119, CASP3, Myokine combi n = 4, p# 5–15; PaCaDD119, CASP7, Myokine combi n = 4, p#
7–16. (B,C) Immunoblot analysis of caspase 3 and 7 expression and PARP cleavage after treatment with myokines. As
described in Figure 6A, Panc1 and PaCaDD119 were serum-deprived and stimulated with a combination of CXCL1, IL10
and CCL4. As a control for cell death-associated PARP cleavage, some cells were treated with 100 µg/mL cycloheximide
(CHX) for 4–6 h before lysis. Cell lysates were analysed using either Casp7, Casp3 (data shown only in the graph) and
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α-Actin, or PARP (full length (fl) and cleaved (cl, 89 kDa fragment)) immunoblotting. Signal intensities were quantified
using ImageJ (including background and protein loading; mean (SD), graphs, number of independent experiments and
passage number: Panc1, Casp3 n = 5, Casp7 n = 3, cl. PARP n = 3, p# 7–16; PaCaDD119, Casp3 n = 5, Casp7 n = 5, cl. PARP
n = 6, p# 5–15). (D,E) PC cells were incubated with 20 ng/mL of CXCL1, IL10, CCL4, CCL22 or LTA, or with a combination
of CXCL1/IL10/CCL4 for 24–48 h (Panc1) or 48–72 h (PaCaDD119). Then, relative cell death was determined by DNA
fragmentation; mean (SD), number of independent experiments and passage number: Panc1, CXCL1 n = 7, IL10 n = 10,
CCL4 n = 10, CCL22 n = 8, LTA n = 8, combi n = 6, p# 8–22; PaCaDD119, CXCL1 n = 7, IL10 n = 5, CCL4 n = 5, CCL22
n = 6, LTA n = 6, combi n = 5, p# 12–19. Additional statistics: Panc1: CCL22 p = 0.7577, LTA p = 0.4351; PaCaDD119: CCL22
p = 0.5770, LTA p = 0.0256. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; paired two-tailed t-test and Student’s t-test in
A; Student’s t-test in (B–E).
4. Discussion
In the study presented here, we investigated the direct effect of resistance training in
advanced aggressive tumour disease on cancer cell lines, in order to gain more knowledge
on the cross-talk between skeletal muscle and tumour.
The exercise-conditioned serum was derived from advanced-stage cancer patients,
with focus on patients with PC, who participated in our pilot study and completed a
12-week WB-EMS training, a form of resistance exercise feasible for physically weakened
cancer patients [20]. We found that the exercise-trained patient serum inhibits the growth
and migration of PC cells, and induces PC cell death. Besides other factors, we identified
higher levels of IL10, CXCL1 and CCL4 in the blood of exercising PC patients. Together
with data from an EPS-based in vitro exercise model using human skeletal muscle cells,
we propose that IL10, CXCL1 and CCL4 are muscle-derived myokines that are induced
by WB-EMS-mediated resistance exercise. We found that single administration of recom-
binant IL10, CXCL1 or CCL4 attenuates the proliferation of PC cells, and simultaneously
induces pro-apoptotic effects, while the stimulation of these cells with a combination of
CXCL1/IL10/CCL4 synergistically increased the observed anti-tumour effects. Further-
more, our results point towards a function of caspase 3 and 7 in exercise-induced apoptosis
of cancer cells and further corroborate the existence of a mechanistic linkage between
muscle activity and cancer cell death. We propose that muscle-derived IL10, CXCL1 and
CCL4 are, at least in part, responsible for the exercise-mediated upregulation of CASP3 and
7 gene expression and consequently their increased protein levels in PC and other cancer
cells. This seems to correlate with enhanced cleavage of PARP, which is an essential step in
apoptotic events and depends on caspase 3/7 activity. Once cleaved, PARP cannot repair
DNA damage, causing DNA fragmentation and ultimately cancer cell death (please see
Figure 7; [43,44]).
The majority of studies, which investigated the effects of exercise-conditioned serum
on cancer, focused either on healthy individuals, patients in an early stage of cancer disease
or cancer survivors [45–47]. We here present evidence that physically weakened patients
with advanced cancer are able to effectively exercise in order to secret muscle-derived
factors with anti-cancer effects. Taken together with the data from our previous report [21],
we show that serum from exercise-trained patients with aggressive gastrointestinal (GI)
cancer (pancreas, stomach), with less aggressive GI tumours (colon/rectum) or non-GI
tumours (prostate) reduce growth and viability of various cancer cells. Our results strongly
suggest that resistance exercise using WB-EMS triggers an anti-tumour response from
skeletal muscle that is independent from the tumour entity. Yet, the limited number of
exercise-trained patients may have affected our promising results. Also, the heterogeneity
of our study population (sex, age, tumour biology) might have influenced the outcome.
To strengthen our observations, a larger and more homogeneous population of patients
should be studied in future research. In our report we focused on the anti-cancer effects
of exercise on tumour cells; however, a pancreatic ductal adenocarcinoma is composed of
various cell types, e.g., cancer-associated fibroblasts. It will be very important to investigate
the impact of WB-EMS-mediated resistance exercise and myokines on other cells of the
tumour microenvironment.
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The aetiology of PC has been extensively analysed. Ninety percent of the PC cases
are diagnosed with a pancreatic ductal adenocarcinoma, which is highly fatal with cur-
rently limited options for early detection and effectiv treatment [28]. Th re is moderate
evidence for an association between higher levels of physical activity and lower occurrence
of PC [28,48]. In recent years, several clinical trials have been conducted with an exercise
intervention in PC patients, focusing on the effects of exercise on physical function and the
psychological condition of the patients [49,50]. However, knowledge about the more direct
effects of exercise to fight this type of malignant tumour disease is scarce. As mentioned,
skeletal muscle releases myokines upon contraction, which allow communication with
various body tissues and the muscle itself. Hundreds of myokines, including interleukins
like IL6 and IL15, and growth factors like BDNF and VEGF, are known, but so far only for a
few myokines a biological function is described [4,6]. Hojman and colleagues reported for
the first time, that conditioned serum from exercising mice decreases growth and viability
of breast cancer cells via exercise-induced factors. Further examination revealed that the
myokine oncostatin M is involved in exercise-induced apoptosis in breast cancer cells [2].
The Hojman group also reported an IL6-dependent mechanism that activates the innate im-
mune defense upon exercise to control tumour growth [11]. SPARC (secreted protein acidic
and rich in cysteine) was also released from skeletal muscle upon contraction and sup-
pressed colon tumourigenesis in exercising mice, primarily via the induction of apoptosis in
colon carcinoma cells [12]. Furthermore, several in vitro studies described FNDC5/irisin as
a myokine with diverse anti-tumour activities in various cancer cells [15–18,51–54]. Gannon
and co-workers demonstrated that irisin suppresses growth and migration of breast cancer
cells [51]. In lung and bone cancer cells it was shown that irisin inhibits cell proliferation,
migration and invasion, and affects epithelial-to-mesenchymal transition (EMT) [18,53].
Cancers 2021, 13, 3820 21 of 27
Liu et al. reported that irisin attenuates migration and invasion of PC cells through in-
hibition of EMT, and suppresses PC cell growth via AMPK/mTOR signalling [16]. It is
important to further examine the anti-migratory effect of serum after WB-EMS exercise
and of the myokines CXCL1, IL10 and CCL4, we have seen in our experiments. Since the
inhibitory effect of exercise serum on PC cell migration was stronger than with myokine
supplementation, other exercise-induced factors, like irisin and its regulation of EMT,
might also play a role in the exercise-mediated regulation of PC mobility. We demonstrated
in our previous study that WB-EMS-mediated resistance exercise regulates cancer cell
growth and viability via the control of exercise-sensitive genes encoding proteins for cell
cycle control, cell growth signalling and the regulation of apoptosis [21]. It is possible
that resistance exercise initiates epigenetic modification, involving e.g., post-translational
modifications of histone proteins or expression of microRNAs [21,55]. Various studies have
shown that physical activity/exercise can induce epigenetic modification in cells of the tu-
mour microenvironment, in natural killer cells and directly in cancer cells, suggesting that
epigenetic changes play a significant role in cancer initiation, progression and invasion [55].
Future studies should give mechanistic insight into how WB-EMS-mediated resistance
exercise and thereby induced myokines affect gene expression in cancer cells.
Our data presented here suggest that resistance exercise using WB-EMS induces the
release of IL10, CXCL1 and CCL4 from skeletal muscle in patients with advanced PC.
In the literature, these cytokines are described as myokines [2,30–32]. IL10 was, among
others, identified as an exercise-induced muscle factor with a minor anti-proliferative
effect on breast cancer cells [2]. Secreted by various immune cells, IL10 participates in
the suppression of cancer-mediated inflammation. Its role in cancer is controversially
discussed, but the majority of studies report anti-proliferative effects on tumour cells [56].
Secreted from activated skeletal muscle, IL10 is mostly described as an anti-inflammatory
regulator with an indirect impact on cancer [57,58]. CXCL1, also named growth-related
oncogene 1 alpha (GRO1α), is an established myokine [30,59]. It plays a major role in
inflammation, angiogenesis, tumourigenesis, and wound healing, and is considered as a
prognostic factor in cancer, but the data are controversial [60,61]. The majority of reports
suggest that CXCL1 promotes tumourigenesis in various cancers. However, we clearly
show (dose-dependent) anti-proliferative and pro-apoptotic effects of recombinant CXCL1
on several PC cell lines, which indicates cancer-protective properties of CXCL1 within our
experimental approach. When induced by contraction in skeletal muscle, CXCL1 regulates
muscle cell differentiation and motility, as well as fatty acid oxidation in the muscle [33,34].
To our knowledge, a direct role of muscle-derived CXCL1 on cancer cells has not been
reported yet. CCL4, also referred to as macrophage inflammatory protein 1 beta (Mip1β),
was described as an exercise-triggered muscle factor [62], but controversial data can be
found in the literature [63–65]. CCL4 is known to be chemoattractant for various immune
cells. There is evidence that CCL4 indirectly promotes cancer development and progression
by recruiting certain immune cells and by influencing cells of the tumour microenvironment
to enhance their pro-tumourigenic capacities [66]. As a myokine, CCL4 participates in
the control of myoblast growth and in wound repair after muscle injury [67,68]. Muscle-
derived CCL4 has not been attributed with direct anti-tumour effects yet. In our previous
report, we suggested that the anti-proliferative and pro-apoptotic effects of exercise on
cancer cells—transmitted via exercise- or EPS-conditioned serum/medium—are caused by
myokines. Based on our data presented here, we have defined three additional mediators
of the anti-tumour effects of exercise. As mentioned before, the established myokines IL6,
irisin and SPARC have cancer-protective functions [11,12,15–18,51–54]. Since we also found
increased mRNA levels of these myokines in human myotubes after exercise-mimicking
EPS, it is possible that IL6, irisin and/or SPARC also contribute to the anti-tumour effects
of our exercise-conditioned patient serum and muscle cell medium.
A major reason for the poor prognosis of patients with pancreatic duct carcinomas is
their insensitivity to most anti-cancer therapeutic approaches. PC is a highly chemoresis-
tant malignancy and most cytotoxic therapies aim to induce apoptosis in these cancer cells.
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Yet, pancreatic duct adenocarcinoma cells have developed multiple molecular alterations
to escape apoptosis and ensure their own survival. They acquired resistance to apoptotic
stimuli such as death ligands or anti-cancer drugs by diverse molecular mechanisms that
either disrupt a pro-apoptotic signal or antagonise apoptosis [69,70]. We demonstrate here
that the expression of caspase 3 and 7 is upregulated by exercise-conditioned serum from
advanced PC patients, by myotube medium conditioned via in vitro exercise, as well as
by a combination of the myokines CXCL1/IL10/CCL4 in different PC cells. Classically,
apoptosis is initiated either via intracellular signals when cells are under stress (intrinsic
pathway) or via extracellular signals activating death receptors on the cell surface (extrinsic
pathway); both pathways ultimately activate the executioner caspases 3, 6 and 7 [69,71].
The upregulation of gene and protein expression of caspases 3 and 7, as shown here, might
be an alternative route to induce apoptosis, whereby the classical initiation of apoptosis is
bypassed: it is possible that the exercise-induced factors CXCL1, IL10 and CCL4 enhance
cancer cell apoptosis by increasing the availability of caspase 3 and 7. Several reports
showed a loss/downregulation of caspase 3 and/or 7 in cancer cells which correlated with
the resistance to apoptosis [72–75]. We observed that higher expression levels of caspase
3 and 7 correlated with enhanced PARP cleavage in PC cells. The cleavage of PARP by
caspase 3/7 separates PARP into 2 segments. The smaller fragment includes the DNA
binding domain, which irreversibly binds to nicked DNA where it acts as inhibitor of
active full length PARP as well as of other DNA repair enzymes; thereby, DNA repair is im-
peded [76]. We observed that DNA fragmentation in PC cells is enhanced after stimulation
with myokines, which ultimately leads to increased PC cell death. Some oncological thera-
peutic regimens include PARP inhibitors as potentiators of chemotherapeutics, leading to
malfunction of DNA repair mechanisms and thus to genomic dysfunction and cancer cell
death [77].
Our data indicate that muscle-derived CXCL1, IL10 and CCL4 are part of the mecha-
nistic link between exercise and the induction of apoptosis in cancer cells. Since there is
discrepancy regarding the anti-cancer impact of CXCL1 and CCL4 between our results
and some data from the literature, it is of interest whether the site of expression deter-
mines different biological functions of CXCL1 and CCL4. It is known that the prototypical
myokine IL6 has a strong pro-inflammatory function when released by immune cells, while
muscle-derived IL6 acts anti-inflammatory [78]. The opposite actions of IL6 seem to be due
to a switch of IL6 signalling from a canonical mode, which occurs in myeloid cells, to a
trans-signalling mode, which can be found in adipocytes and muscle cells; an increased
expression of the ADAM10/17 metalloprotease promotes the trans-signalling via the sol-
uble IL6 receptor α [4]. More research is necessary to investigate if similar mechanisms
determine tumour-inhibitory vs. pro-tumour effects of CXCL1 and CCL4. Additionally, it
will be important to examine whether the induction of this set of myokines after exercise is
universal. Not much is known about how different types of exercise induce different sets
of myokines. It needs to be clarified if CXCL1, IL10 and/or CCL4 are rather specifically
released after resistance exercise or are also induced by endurance training. Furthermore,
our data suggest that WB-EMS-mediated resistance exercise triggers a comparable anti-
tumour response in patients with different GI and non-GI tumour diseases. So far, we
have identified CXCL1, IL10 and CCL4 in exercise-conditioned serum of advanced PC
patients; it will be important to know if these myokines are generally induced by exercise,
independent of the tumour type and its characteristics (e.g., aggressiveness or hormone
dependency). The patients’ physical status might also affect myokine availability. For the
well-characterised IL6, it is reported to increase exponentially during exercise and that the
extent of the IL6 surge depends on the amount of activated skeletal muscle mass [79]. It was
also shown that circulating levels and muscle levels differ for certain myokines in patients
with cancer cachexia vs. non-cachectic cancer patients [80], indicating that the amount
of muscle mass and/or the “quality” of muscle contraction is a significant parameter in
the regulation of myokine release. Detailed knowledge about the expression conditions
and dynamics of post-exercise secretory factors with anti-tumour function would be very
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important for cancer patients. Multimodal therapeutic concepts could then include highly
personalised physical training programs with the best anti-cancer impact.
5. Conclusions
Regular physical exercise reduces the cancer risk, but the exercise-malignancy relation-
ship is not fully understood. Several myokines, that are released by skeletal muscle, have
direct anti-tumour function. We believe we have identified additional exercise-induced
myokines with cancer-protective properties in patients with advanced PC. We could show
that IL10, CXCL1 and CCL4 inhibit growth and migration of PC cells, and induce apop-
totic events. The identification of myokines with anti-tumour function in patients with
advanced-stage PC after exercise strongly supports sport therapies for cancer patients.
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